Market capitalization | $11.59m |
Enterprise Value | $7.49m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.69 |
P/S ratio (TTM) P/S ratio | 2.62 |
P/B ratio (TTM) P/B ratio | 1.19 |
Revenue growth (TTM) Revenue growth | 40.41% |
Revenue (TTM) Revenue | $4.42m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Ensysce Biosciences Inc:
1 Analyst has issued a forecast Ensysce Biosciences Inc:
Sep '24 |
+/-
%
|
||
Revenue | 4.42 4.42 |
40%
40%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -6.31 -6.31 |
54%
54%
|
EBIT (Operating Income) EBIT | -6.31 -6.31 |
54%
54%
|
Net Profit | -7.93 -7.93 |
37%
37%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.
Head office | United States |
CEO | D. Kirkpatrick |
Employees | 9 |
Founded | 2003 |
Website | www.ensysce.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.